{"doi":"10.1111/jdv.13940","title":"Melanoma antigens are biomarkers for ipilimumab response","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, <jats:styled-content style=\"fixed-case\">CTLA</jats:styled-content>‐4‐blocking monoclonal antibody ipilimumab is effective only in a small proportion of patients. Biomarkers for prediction of treatment response are indispensably needed.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To determine the utility of multimarker detection of circulating melanoma cells as prognostic and pharmacodynamic biomarker in patients with metastatic melanoma treated with ipilimumab.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients (<jats:italic>n</jats:italic> = 62) with metastatic melanoma in unresectable stage <jats:styled-content style=\"fixed-case\">III</jats:styled-content> or metastatic stage <jats:styled-content style=\"fixed-case\">IV</jats:styled-content> treated with ipilimumab were recruited prospectively. The values of four melanoma markers on circulating cells Melan‐A, gp100, <jats:styled-content style=\"fixed-case\">MAGE</jats:styled-content>‐3 and melanoma inhibitory antigen prior to the treatment and within the therapy were compared to the data collected at baseline – after the melanoma surgery.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The immunotherapy pretreatment marker level was found to be prognostic of overall survival; lower levels were linked to longer survival time. Moreover, longitudinal follow‐up of melanoma markers in patients treated with ipilimumab correlates with therapy response. A decline of marker levels by &gt;30% at week 6 (in 83% of the responding subjects) to week 9 (in all responders) of ipilimumab administration was associated with response to therapy. Elevation of the tumour markers during the treatment precedes clinical progression and gives an early warning of treatment failure.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Melanoma circulating cells hold potential as predictive and pharmacodynamic biomarker of immunotherapy.</jats:p></jats:sec>","journal":"Journal of the European Academy of Dermatology and Venereology","year":2017,"id":642280,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1670459,"name":"A. Fialova","orcid":null,"position":1,"is_corresponding":false},{"id":1670460,"name":"S. Gkalpakiotis","orcid":null,"position":2,"is_corresponding":false},{"id":1670461,"name":"A. Pavlikova","orcid":null,"position":3,"is_corresponding":false},{"id":1670462,"name":"I. Puzanov","orcid":null,"position":4,"is_corresponding":false},{"id":1670463,"name":"M. Arenbergerova","orcid":null,"position":5,"is_corresponding":false},{"id":1670457,"name":"P. Arenberger","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Melanoma antigens are biomarkers for ipilimumab response","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, <jats:styled-content style=\"fixed-case\">CTLA</jats:styled-content>‐4‐blocking monoclonal antibody ipilimumab is effective only in a small proportion of patients. Biomarkers for prediction of treatment response are indispensably needed.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To determine the utility of multimarker detection of circulating melanoma cells as prognostic and pharmacodynamic biomarker in patients with metastatic melanoma treated with ipilimumab.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients (<jats:italic>n</jats:italic> = 62) with metastatic melanoma in unresectable stage <jats:styled-content style=\"fixed-case\">III</jats:styled-content> or metastatic stage <jats:styled-content style=\"fixed-case\">IV</jats:styled-content> treated with ipilimumab were recruited prospectively. The values of four melanoma markers on circulating cells Melan‐A, gp100, <jats:styled-content style=\"fixed-case\">MAGE</jats:styled-content>‐3 and melanoma inhibitory antigen prior to the treatment and within the therapy were compared to the data collected at baseline – after the melanoma surgery.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The immunotherapy pretreatment marker level was found to be prognostic of overall survival; lower levels were linked to longer survival time. Moreover, longitudinal follow‐up of melanoma markers in patients treated with ipilimumab correlates with therapy response. A decline of marker levels by &gt;30% at week 6 (in 83% of the responding subjects) to week 9 (in all responders) of ipilimumab administration was associated with response to therapy. Elevation of the tumour markers during the treatment precedes clinical progression and gives an early warning of treatment failure.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Melanoma circulating cells hold potential as predictive and pharmacodynamic biomarker of immunotherapy.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27557295","pmcid":null,"openalex_id":"https://openalex.org/W2513285370","authors":[],"funders":[{"funder_name":"Czech Ministry of Health","grant_id":"IGA NT 14440-3/2013","title":null}],"total_grants":1,"fwci":1.0079,"citation_percentile":0.78646621,"influential_citations":0,"citation_trend":[{"year":2016,"count":1},{"year":2017,"count":2},{"year":2018,"count":2},{"year":2019,"count":2},{"year":2020,"count":1},{"year":2025,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjdv.13940","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.13940","host_type":"publisher"},{"url":"https://doi.org/10.1111/jdv.13940","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/27557295","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Immunotherapy and Immune Responses","Melanoma and MAPK Pathways"],"mesh_terms":["Ipilimumab","Adult","Aged","Antibodies, Monoclonal","Female","Humans","Immunotherapy","Male","Melanoma","Middle Aged","Prognosis","Biomarkers, Tumor","Young Adult","Melanoma-Specific Antigens"],"keywords":["Medicine","Ipilimumab","Melanoma","Antigen","Immunology","Oncology","Immunotherapy","Cancer research","Immune system"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T22:11:27.874338Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}